# QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia

Study · id `cardio:ct-nct07444086` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07444086](<https://clinicaltrials.gov/study/NCT07444086>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07444086

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 510 participants.

## Technical summary

Registry record NCT07444086. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-05 (anticipated); primary completion 2027-10-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 510 participants (planned count; ClinicalTrials.gov record NCT07444086, source copy `cardio:ctgov-nct07444086-2026-03-02`, retrieved 2026-10-31)
- Planned start: 2026-03-05 (anticipated) (ClinicalTrials.gov record NCT07444086, source copy `cardio:ctgov-nct07444086-2026-03-02`, retrieved 2026-10-31)
- Primary completion: 2027-10-07 (anticipated) (ClinicalTrials.gov record NCT07444086, source copy `cardio:ctgov-nct07444086-2026-03-02`, retrieved 2026-10-31)
- Completion: 2028-02-28 (anticipated) (ClinicalTrials.gov record NCT07444086, source copy `cardio:ctgov-nct07444086-2026-03-02`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07444086-2026-03-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia
- Condition: Primary Hypercholesterolemia or Mixed Hyperlipidemia
- Intervention (Drug): QLC7401
- Intervention (Drug): Placebo
- Lead sponsor: Qilu Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Qilu Pharmaceutical Co., Ltd. (`cardio:org-qilu-pharmaceutical-co-ltd`)

## Provenance

Content hash: 32e9e5ddf73c820a5b3734f2ac098441381de11fc2287e5e4b99f54e27eb8397
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
